New Cell Therapy CGMP Manufacturing Facility to Open in California
Thermo Fisher Scientific (MA, USA) has announced a ‘strategic alliance’ with the University of California, San Francisco (UCSF; CA, USA) to open a cell therapy cGMP manufacturing and collaboration centre on the university’s Mission Bay campus.
In a news release from Thermo Fisher Scientific, the company claims the new facility will provide an end-to-end solution for accelerating the development and manufacturing of cell therapies, offering both clinical and commercial opportunities.
“We are bringing together UCSF‘s leadership in the newest forms of cellular immunotherapy and Thermo Fisher’s extensive capabilities in cell therapy instrumentation, manufacturing and distribution,” explained Mark Stevenson, Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific.
The agreement stipulates that Thermo Fisher Scientific will build a 44,000 square-foot centre on leased space on the UCSF Mission Bay campus, which is already home to several biomedical research facilities and hospitals.
“We expect breakthrough treatments for many different diseases and conditions to come from cell therapies. Establishing cell therapy manufacturing in such close proximity to our scientists, clinicians and patients will enable UCSF to catalyse innovation in living therapeutics and use the resulting discoveries to benefit our patients,” Sam Hawgood, Chancellor of UCSF, commented.
With an anticipated opening date in 2022, Thermo Fisher Scientific will also be responsible for operating the facility, offering clinical and commercial cGMP cell therapy manufacturing services as well as other support opportunities to UCSF and partners.
The facility will reportedly further serve as a ‘central location’ for UCSF researchers and customers to access reagents, consumables, fit-for-purpose instrumentation and compliant software already established within the Thermo Fisher Cell Therapy Systems portfolio.
“This powerful combination will provide customers – from emerging biotechs to large pharma companies – with integrated, end-to-end solutions to reduce costs and accelerate adoption of cell therapies, ultimately improving patient access to these transformative treatments,” Stevenson concluded.